HFI-419

HFI-419 is an insulin-regulated aminopeptidase (IRAP) inhibitor. HFI-419 has inhibitory potency for IRAP with Ki value of 0.48 μM. HFI-419 can be used for the research of cognitive and memory impairments such as Alzheimer's disease, brain trauma, and stroke[1].

Signaling Pathways >> Metabolic Enzyme/Protease >> Aminopeptidase

Research Areas >> Neurological Disease

Ki: 0.48 μM (IRAP)[1]

HFI-419 inhibits IRAP with a Ki value of 0.48 μM[1]. HFI-419 (1 μM) shows rapid disappearance that is associated with nonenzymatic (such as amide hydrolysis) processes[1].

HFI-419 (i.v, i.p; 2, 10 mg/kg) exhibits brain exposure and also exhibits potent inhibition of IRAP[1]. Animal Model: Sprague-Dawley rats[1] Dosage: 2 mg/kg, 10 mg/kg Administration: Intravenous, intraperitoneal Result: Exhibited a short apparent elimination half-life, a high plasma clearance and a large volume of distribution. Extended the apparent half-life to 4.6 h.